Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter F Orio III, D.O.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Yang DD, Muralidhar V, Mahal BA, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Martin NE, King MT, Mouw KW, Choueiri TK, Trinh QD, Nguyen PL, Orio PF. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol. 2020 Jul 09. PMID: 32654951.
    Citations:    
  2. Perni S, Milligan MG, Saraf A, Vivenzio T, Marques A, Baker MA, Kosak T, Bartlett S, Physic MA, Batchelder MR, McBride S, Bredfeldt J, Cail DW, Kearney MC, Whitehouse C, Orio P, Walsh G, Haas-Kogan DA, Martin NE. Treating the SARS-CoV-2-positive patient with cancer: A proposal for a pragmatic and transparent ethical process. Cancer. 2020 May 28. PMID: 32463478.
    Citations:    
  3. Oladeru OT, Yang DD, Ma SJ, Miccio JA, Orio PF, Warren LE. Patterns of care and predictors of adjuvant radiation therapy in phyllodes tumor of the breast. Breast J. 2020 Jul; 26(7):1352-1357. PMID: 32275108.
    Citations:    
  4. Shinde A, Li R, Amini A, Vapiwala N, Orio P, Vargo JA, Yashar C, Chen YJ, Beriwal S, Glaser S. Resident experience in brachytherapy: An analysis of Accreditation Council for Graduate Medical Education case logs for intracavitary and interstitial brachytherapy from 2007 to 2018. Brachytherapy. 2019 Dec 12. PMID: 31839568.
    Citations:    
  5. Muralidhar V, Mahal BA, Butler S, Lamba N, Yang DD, Leeman J, D'Amico AV, Nguyen PL, Trinh QD, Orio PF, King MT. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019 11; 202(5):973-978. PMID: 31144590.
    Citations:    
  6. Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948. PMID: 31390585.
    Citations:    
  7. Alimena S, Yang DD, Melamed A, Mahal BA, Worley MJ, Feldman S, Elias KM, Orio PF, Lee LJ, King M. Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecol Oncol. 2019 09; 154(3):595-601. PMID: 31292103.
    Citations:    
  8. Brenneman RJ, Soffen E, Gay HA, Orio PF, Christodouleas JP, Baumann JC, Baumann BC. Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526). Transl Androl Urol. 2019 Jul; 8(Suppl 3):S265-S270. PMID: 31392141.
    Citations:    
  9. King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191. PMID: 30638912.
    Citations:    Fields:    
  10. King MT, Nguyen PL, Boldbaatar N, Yang DD, Muralidhar V, Tempany CM, Cormack RA, Hurwitz MD, Suh WW, Pomerantz MM, D'Amico AV, Orio PF. Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy. 2019 Mar - Apr; 18(2):198-203. PMID: 30638910.
    Citations:    Fields:    
  11. King MT, Nguyen PL, D'Amico AV, Orio PF. Reply to Partial gland therapy for prostate cancer. Cancer. 2019 03 01; 125(5):819-820. PMID: 30570738.
    Citations:    Fields:    
  12. Orio PF, Goodwin J. In Regard to Bauer-Nilsen et al. Int J Radiat Oncol Biol Phys. 2018 12 01; 102(5):1598-1599. PMID: 31014792.
    Citations:    
  13. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41. PMID: 30554605.
    Citations:    
  14. Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF, King MT, Nguyen PL. Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959. PMID: 29045266.
    Citations:    Fields:    
  15. King MT, Nguyen PL, Boldbaatar N, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV, Orio PF. Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer. 2018 09 01; 124(17):3528-3535. PMID: 29975404.
    Citations:    Fields:    
  16. Guthier CV, D'Amico AV, King MT, Nguyen PL, Orio PF, Sridhar S, Makrigiorgos GM, Cormack RA. Determining optimal eluter design by modeling physical dose enhancement in brachytherapy. Med Phys. 2018 Jun 15. PMID: 29905964.
    Citations:    Fields:    
  17. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154. PMID: 29478736.
    Citations:    Fields:    
  18. King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20. PMID: 29276060.
    Citations:    Fields:    Translation:Humans
  19. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149. PMID: 29231964.
    Citations: 1     Fields:    
  20. Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer. 2018 06; 16(3):226-234. PMID: 29196209.
    Citations:    Fields:    
  21. Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):53-58. PMID: 29254781.
    Citations: 1     Fields:    Translation:Humans
  22. Rotenstein LS, Agarwal A, O'Neil K, Kelly A, Keaty M, Whitehouse C, Kalinowski B, Orio PF, Wagle N, Martin NE. Implementing patient-reported outcome surveys as part of routine care: lessons from an academic radiation oncology department. J Am Med Inform Assoc. 2017 Sep 01; 24(5):964-968. PMID: 28339771.
    Citations: 1     Fields:    Translation:Humans
  23. Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF, King MT, Nguyen PL. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840. PMID: 28832984.
    Citations:    Fields:    Translation:Humans
  24. Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF, King MT. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):904-911. PMID: 29063853.
    Citations: 1     Fields:    Translation:Humans
  25. Buzurovic IM, Salinic S, Orio PF, Nguyen PL, Cormack RA. A novel approach to an automated needle insertion in brachytherapy procedures. Med Biol Eng Comput. 2018 Feb; 56(2):273-287. PMID: 28712013.
    Citations:    Fields:    Translation:Humans
  26. Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76. PMID: 28753811.
    Citations: 1     Fields:    
  27. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 09; 35(9):542.e25-542.e32. PMID: 28533151.
    Citations:    Fields:    Translation:Humans
  28. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343. PMID: 28463152.
    Citations:    Fields:    Translation:Humans
  29. Thaker NG, Orio PF, Potters L. Defining the value of magnetic resonance imaging in prostate brachytherapy using time-driven activity-based costing. Brachytherapy. 2017 Jul - Aug; 16(4):665-671. PMID: 28187994.
    Citations: 2     Fields:    
  30. Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):186-192. PMID: 28117383.
    Citations: 5     Fields:    Translation:Humans
  31. Bittner NH, Orio PF, Merrick GS, Prestidge BR, Hartford AC, Rosenthal SA. The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer. Brachytherapy. 2017 Jan - Feb; 16(1):59-67. PMID: 28109632.
    Citations: 2     Fields:    Translation:Humans
  32. Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3. PMID: 28462857.
    Citations:    Fields:    Translation:Humans
  33. Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700. PMID: 27528590.
    Citations:    Fields:    Translation:Humans
  34. Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW. Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):624-8. PMID: 27681758.
    Citations: 3     Fields:    Translation:Humans
  35. Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy. 2016 Nov - Dec; 15(6):701-706. PMID: 27317191.
    Citations: 2     Fields:    Translation:Humans
  36. Chapman TR, Laramore GE, Bowen SR, Orio PF. Neutron radiation therapy for advanced thyroid cancers. Adv Radiat Oncol. 2016 Jul-Sep; 1(3):148-156. PMID: 28740884.
    Citations:    
  37. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. PMID: 26970022.
    Citations: 5     Fields:    Translation:Humans
  38. O'Neil K, Kelly A, Keaty M, Whitehouse C, Kalinowski B, Orio PF, Martin NE. Implementing patient-reported outcome surveys as part of routine care: Lessons from an academic radiation oncology department. J Clin Oncol. 2016 Mar; 34(7_suppl):97. PMID: 28152817.
    Citations:    
  39. Muralidhar V, Xiang M, Orio PF, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6. PMID: 26985191.
    Citations: 5     
  40. Thaker NG, Pugh TJ, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orio PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ. Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy. 2016 May-Jun; 15(3):274-282. PMID: 26916105.
    Citations: 4     Fields:    Translation:Humans
  41. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. PMID: 26972640.
    Citations: 8     Fields:    Translation:Humans
  42. Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32. PMID: 26391387.
    Citations: 1     Fields:    Translation:Humans
  43. Merrick GS, Wallner KE, Galbreath RW, Butler WM, Fiano R, Orio PF, Adamovich E. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials. Brachytherapy. 2015 Sep-Oct; 14(5):677-85. PMID: 26051802.
    Citations: 6     Fields:    Translation:Humans
  44. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8. PMID: 25845283.
    Citations: 1     Fields:    Translation:Humans
  45. Muralidhar V, Mahal BA, Ziehr DR, Chen YW, Nezolosky MD, Viswanathan VB, Beard CJ, Devlin PM, Martin NE, Orio PF, Nguyen PL. Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6. PMID: 25887342.
    Citations: 1     Fields:    Translation:Humans
  46. Schutzer ME, Orio PF, Biagioli MC, Asher DA, Lomas H, Moghanaki D. A review of rectal toxicity following permanent low dose-rate prostate brachytherapy and the potential value of biodegradable rectal spacers. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):96-103. PMID: 25687401.
    Citations: 2     Fields:    Translation:Humans
  47. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9. PMID: 25681290.
    Citations: 21     Fields:    Translation:Humans
  48. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16. PMID: 25644324.
    Citations: 4     Fields:    Translation:Humans
  49. Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hoffman KE, Hu JC, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406. PMID: 25430935.
    Citations: 2     Fields:    Translation:Humans
  50. Inverso G, Aizer AA, Ziehr DR, Hyatt A, Choueiri TK, Hoffman KE, Hu JC, Beard C, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Incidence and determinants of 1-month mortality after cancer-directed surgery. J Clin Oncol. 2014 Oct 20; 32(30_suppl):282. PMID: 28141239.
    Citations:    
  51. Murciano-Goroff YR, Wolfsberger LD, Parekh A, Fennessy FM, Tuncali K, Orio PF, Niedermayr TR, Suh WW, Devlin PM, Tempany CM, Sugar EH, O'Farrell DA, Steele G, O'Leary M, Buzurovic I, Damato AL, Cormack RA, Fedorov AY, Nguyen PL. Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. Radiat Oncol. 2014 Sep 09; 9:200. PMID: 25205146.
    Citations: 2     Fields:    Translation:Humans
  52. Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9. PMID: 24880584.
    Citations: 4     Fields:    Translation:Humans
  53. Niedermayr TR, Nguyen PL, Murciano-Goroff YR, Kovtun KA, Neubauer Sugar E, Cail DW, O'Farrell DA, Hansen JL, Cormack RA, Buzurovic I, Wolfsberger LT, O'Leary MP, Steele GS, Devlin PM, Orio PF. Placement of empty catheters for an HDR-emulating LDR prostate brachytherapy technique: comparison to standard intraoperative planning. Brachytherapy. 2014 Jul-Aug; 13(4):375-9. PMID: 24613569.
    Citations:    Fields:    Translation:Humans
  54. Kovtun KA, Wolfsberger L, Niedermayr T, Sugar EN, Graham PL, Murciano-Goroff Y, Beard C, D'Amico AV, Martin NE, Orio PF, Nguyen PL. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy. 2014 Mar-Apr; 13(2):152-6. PMID: 23911279.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  55. Wolfsberger LD, Niedermayr T, Neubauer E, Murciano-Goroff YR, Beard C, D'Amico AV, Martin NE, Orio PF, Nguyen PL. Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. J Clin Oncol. 2013 Feb 20; 31(6_suppl):232. PMID: 28136851.
    Citations:    
  56. Orio PF, Merrick GS, Galbreath RW, Butler WM, Lief J, Wallner KE. Patient-reported long-term rectal function after permanent interstitial brachytherapy for clinically localized prostate cancer. Brachytherapy. 2012 Sep-Oct; 11(5):341-7. PMID: 22561216.
    Citations: 2     Fields:    Translation:Humans
  57. Nguyen PL, Devlin PM, Beard CJ, Orio PF, O'Leary MP, Wolfsberger LD, O'Farrell DA, Sweeney CM, Hadaschik BA, Hohenfellner M, Hatiboglu G. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy. 2013 Jan-Feb; 12(1):77-83. PMID: 22543116.
    Citations: 4     Fields:    Translation:HumansPHPublic Health
  58. Tseng YD, Chen MH, Beard CJ, Martin NE, Orio PF, Loffredo M, Renshaw AA, Choueiri TK, Hu JC, Kantoff PW, D'Amico AV, Nguyen PL. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73. PMID: 22498212.
    Citations: 4     Fields:    Translation:Humans
  59. Murciano-Goroff YR, Wolfsberger LD, Parekh A, Fennessy FM, Tuncali K, Orio PF, Niedermayr T, Suh WW, Devlin PM, Tempany CM, Nguyen PL. Variability in prostate volume as determined by MRI versus ultrasound and its impact on treatment recommendations for patients with favorable-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):249. PMID: 28143244.
    Citations:    
  60. Merrick GS, Wallner KE, Butler WM, Galbreath RW, Taira AV, Orio P, Adamovich E. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e449-55. PMID: 22196131.
    Citations: 2     Fields:    Translation:Humans
  61. Kishan AU, Chen MH, Loffredo M, Kim D, Beard CJ, Hurwitz MD, Martin NE, Orio PF, Kantoff PW, D'Amico AV, Nguyen PL. Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-178. PMID: 24674120.
    Citations:    Fields:    
  62. Orio PF, Merrick GS, Allen ZA, Butler WM, Wallner KE, Kurko BS, Galbreath RW. cExternal beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer. Radiat Oncol. 2009 Jul 22; 4:26. PMID: 19624852.
    Citations: 1     Fields:    Translation:Humans
  63. Orio PF, Merrick GS, Grimm P, Blasko J, Sylvester J, Allen ZA, Butler WM, Chaudhry UU. Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of the Pro-Qura database. Am J Clin Oncol. 2008 Dec; 31(6):523-31. PMID: 19060582.
    Citations:    Fields:    Translation:Humans
  64. Bittner N, Wallner K, Merrick G, Orio P, Nurani R, True L. The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure. Am J Clin Oncol. 2008 Jun; 31(3):231-6. PMID: 18525300.
    Citations: 1     Fields:    Translation:Humans
  65. Herstein A, Wallner K, Merrick G, Orio P, Thornton K, Butler W, Sutlief S. There is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapy. Am J Clin Oncol. 2008 Feb; 31(1):6-10. PMID: 18376221.
    Citations: 2     Fields:    Translation:Humans
  66. Mitsuyama H, Wallner K, Merrick G, Virgin J, Orio P, Montgomery B, True LD. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy. Am J Clin Oncol. 2007 Dec; 30(6):597-600. PMID: 18091053.
    Citations:    Fields:    Translation:Humans
  67. Nurani R, Wallner K, Merrick G, Virgin J, Orio P, True LD. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma. J Urol. 2007 Nov; 178(5):1968-73; discussion 1973. PMID: 17868717.
    Citations: 2     Fields:    Translation:Humans
  68. Orio PF, Tutar IB, Narayanan S, Arthurs S, Cho PS, Kim Y, Merrick G, Wallner KE. Intraoperative ultrasound-fluoroscopy fusion can enhance prostate brachytherapy quality. Int J Radiat Oncol Biol Phys. 2007 Sep 01; 69(1):302-7. PMID: 17707285.
    Citations: 7     Fields:    Translation:Humans
  69. Orio P, Wallner K, Merrick G, Herstein A, Mitsuyama P, Thornton K, Butler W, Sutlief S. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):342-6. PMID: 17236959.
    Citations: 3     Fields:    Translation:Humans
  70. Orio P, Stelzer KJ, Goodkin R, Douglas JG. Treatment of arteriovenous malformations with linear accelerator-based radiosurgery compared with Gamma Knife surgery. J Neurosurg. 2006 Dec; 105 Suppl:58-63. PMID: 18503331.
    Citations: 3     Fields:    Translation:Humans
  71. Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF, Skoglund S, Galbreath RW, Merrick G. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys. 2007 Jan 01; 67(1):57-64. PMID: 17084544.
    Citations: 30     Fields:    Translation:Humans
  72. Nurani RD, Wallner KE, Merrick GS, Orio P, Virgin J, True L. The prognostic value of percent positive biopsies in intermediate to high risk prostate cancer treated with brachytherapy and supplemental beam radiotherapy. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4645. PMID: 27952435.
    Citations:    
  73. Orio PF, Dahiya R, Herman T, Thomas CR, Eng TY. Malignant fibrous histiocytoma of the spermatic cord: a case report. Am J Clin Oncol. 2002 Jun; 25(3):227-9. PMID: 12040277.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Orio's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (160)
Explore
_
Co-Authors (47)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.